Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib + Ezetimibe in Dyslipidemia (ROSE2)
NCT05266586Phase 2Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Mar 2022
- Primary completion
- Aug 2022
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of obicetrapib in hypercholesterolemia, dyslipidemia, sponsored by NewAmsterdam Pharma. Started Mar 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on NCT05266586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266586.